Friday, July 10, 2026

pharma · Severe Alpha-1 Antitrypsin Deficiency (AATD)

Grifols

Grifols clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

ES HQ
1909 Founded
14,121 Employees
EMA registrant Type
Company details
Status
Public
HQ
ES
Founded
1909
Employees
14,121
Programs
2
Drugs
2
Patents
0
Intelligence · Clinical Programs

Grifols projects

2 ClinicalTrials.gov programs sponsored by Grifols.

Grifols has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Albutein 50 g/l solución para perfusión.

    Instituto Grifols S.A.

    Subjects with cirrhosis with ACLF-1b, ACLF-2, or ACLF-3a detected either at admission or during hospitalization

    phase 3 small molecule active

    1 trial
  2. PPRO24-001

    Instituto Grifols S.A.

    Severe Alpha-1 Antitrypsin Deficiency (AATD)

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Grifols have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.